Fresolimumab (GC1008) is a human monoclonal antibody against TGF-beta that neutralizes all mammalian active subtypes of TGF-beta. The binding affinity of Fresolimumab to TGF-beta2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-beta expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease[1][2][3][4].
Molecular Weight:
(144.4 kDa)
Purity:
99.51
CAS Number:
[948564-73-6]
Target:
TGF-beta/Smad
Application Notes:
Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted